Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 3, 1998, Pages 317-321

  Patel, Shreyaskumar R ^a   Vadhan Raj, Saroj ^a   Burgess, M Andrew ^a   Plager, Carl ^a   Papadopolous, Nicholas ^a   Jenkins, Jan ^a   Benjamin, Robert S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Dose intensive chemotherapy; Doxorubicin; Ifosfamide; Sarcomas; Soft tissue tumors

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; THROMBOPOIETIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TOXICITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; NEUTROPENIA; SARCOMA; SOFT TISSUE TUMOR; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; SARCOMA;

EID: 0031865087     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199806000-00025     Document Type: Article

References (10)

1. O'Bryan R, Baker L, Gottlieb J, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977;39:1940-8.
2. Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M. D. Anderson experience. Cancer Chemother Pharmacol 1993; 31(suppl 2):S174-9.
3. Antman K, Crowley J, Balcerzak S, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-85.
4. Edmonson J, Ryan L, Blum R, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxoroubicn and cisplatin against soft tissue sarcomas. J Clin Oncol 1993;11:1269-75.
5. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-45.
6. Bramwell V, Quirt I, Warr D, et al. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. J Natl Cancer Inst 1989;81:1496-9.
7. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:1208-16.
8. Patel S, Benjamin R. Ifosfamide in sarcoma: is it a schedule- dependent drug? Cancer Invest 1996;14:290-1.
9. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989;7:126-31.
10. Vadhan-Raj S, Patel S, Burgess M, et al. Phase II trial of adriamycin (A), ifosfamide (I), mesna (M) uroprotection, dacarbazine (D) (MAID) with PIXY321 (GM-CSF/IL-3 fusion protein) or G- CSF in patients (PTS) with soft tissue sarcoma (STS) [Abstract]. Proceedings of the American Society of Clinical Oncology 1996;15:525.